A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer
Impact of Neoadjuvant Endocrine Therapy on Surgical Outcomes in Patients With Stage 2 to 3 Invasive Lobular Carcinoma: A Prospective Study
Memorial Sloan Kettering Cancer Center
176 participants
Mar 13, 2026
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to look at how effective neoadjuvant (before surgery) endocrine therapy (NET) is in participants with invasive lobular carcinoma (ILC) who have breast-conserving surgery (BCS). The main purpose of the study is to see if NET reduces the chance of having cancer cells at the edges of tissue removed during surgery (positive margins).
Eligibility
Inclusion Criteria5
- Written informed consent by participant or legally authorized representative
- Postmenopausal women aged ≥50 years with biopsy-proven cT2-T3 N0-1 ILC who opt to undergo and are medically fit to undergo BCS at enrollment.
- Tumors of the ER+/HER2- subtype, defined as:
- ER+: Positive for ER staining as indicated by ≥10% immunoreactive tumor nuclei.
- HER2-: Immunohistochemistry assay demonstrating no or faint staining in ≤10% of tumor cells (IHC 0 or 1+) or negative by dual probe in situ hybridization assay.
Exclusion Criteria5
- Patients with prior ipsilateral breast cancer.
- Patients with advanced regional disease (cN2/cN3) or stage 4 disease.
- Patients who would benefit from neoadjuvant chemotherapy, per the treating medical oncologist.
- Patients who are not candidates for definitive breast surgery (inoperable or stage 4 disease).
- Patients with gadolinium allergy, precluding the use of breast MRI.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The endocrine therapy used for the NET in this study will be anastrozole, letrozole, exemestane, or tamoxifen.
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07483307